Last 48 quarters of trend data · Healthcare · Medical - Equipment & Services
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Labcorp Holdings Inc.'s quarterly P/E stands at 19.9x, down 13.8% year-over-year — suggesting improving earnings relative to price.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 24.46 | 19.91 | 31.68 | 23.00 | 23.11 | 23.09 | 33.72 | 27.80 | 20.85 | 20.30 | — | 23.82 | 24.45 |
| — | -13.8% | -6.1% | -17.2% | +10.8% | +13.7% | — | +16.7% | -14.7% | -1.5% | — | +110.7% | +88.0% | |
| P/S Ratio | 1.51 | 1.56 | 1.48 | 1.69 | 1.56 | 1.47 | 1.45 | 1.44 | 1.33 | 1.46 | 1.59 | 1.43 | 1.52 |
| — | +6.6% | +2.4% | +17.3% | +17.5% | +0.7% | -8.8% | +0.4% | -12.4% | +0.9% | +29.8% | +2.8% | -4.7% | |
| P/B Ratio | 2.48 | 2.53 | 2.42 | 2.76 | 2.60 | 2.36 | 2.39 | 2.30 | 2.14 | 2.32 | 2.45 | 2.22 | 2.10 |
| — | +7.3% | +1.0% | +19.7% | +21.6% | +1.6% | -2.1% | +4.0% | +2.1% | +37.0% | +37.4% | +40.4% | +17.0% | |
| P/FCF | 17.46 | 78.43 | 10.64 | 21.41 | 10.17 | — | 7.26 | 29.20 | 9.91 | — | 11.70 | 25.63 | 19.40 |
| — | — | +46.6% | -26.7% | +2.6% | — | -38.0% | +13.9% | -48.9% | — | +39.2% | +73.7% | +78.4% | |
| EV / EBITDA | 12.62 | 12.66 | 12.41 | 13.50 | 12.38 | 13.07 | 16.19 | 15.08 | 12.66 | 12.81 | — | 13.07 | 13.44 |
| — | -3.2% | -23.3% | -10.5% | -2.2% | +2.1% | — | +15.3% | -5.9% | +3.1% | — | +21.8% | +21.5% | |
| EV / EBIT | 18.29 | 18.32 | 28.04 | 19.50 | 19.33 | 19.45 | 25.35 | 24.01 | 18.13 | 17.70 | 28.29 | 19.98 | 22.30 |
| — | -5.8% | +10.6% | -18.8% | +6.6% | +9.9% | -10.4% | +20.2% | -18.7% | -2.4% | -55.6% | +32.5% | +50.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Labcorp Holdings Inc.'s operating margin was 10.9% in Q1 2026, up 0.1 pp QoQ and up 1.2 pp YoY. Gross margin contracted 6.4% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 26.8% | 26.5% | 26.2% | 28.8% | 29.7% | 28.3% | 26.9% | 27.6% | 28.8% | 28.2% | 27.1% | 27.8% | 27.8% |
| — | -6.4% | -2.7% | +4.4% | +3.1% | +0.3% | -0.6% | -1.0% | +3.6% | +0.9% | +2.6% | -9.9% | -13.9% | |
| Operating Margin | 10.9% | 10.9% | 10.9% | 11.1% | 11.2% | 9.7% | 6.5% | 7.7% | 9.2% | 10.1% | -4.0% | 8.3% | 8.8% |
| — | +12.3% | +67.1% | +43.8% | +22.2% | -3.6% | +260.6% | -6.2% | +4.3% | -6.8% | -264.0% | -36.7% | -40.2% | |
| Net Margin | 6.3% | 7.9% | 4.7% | 7.3% | 6.7% | 6.4% | 4.3% | 5.2% | 6.4% | 7.2% | -5.5% | 6.0% | 6.2% |
| — | +23.4% | +8.8% | +42.0% | +5.8% | -11.4% | +178.2% | -14.0% | +2.4% | +2.4% | -366.0% | -51.3% | -49.2% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.5% | 3.2% | 1.9% | 3.0% | 2.8% | 2.6% | 1.8% | 2.1% | 2.6% | 2.9% | -2.1% | 2.2% | 2.0% |
| — | +23.1% | +7.6% | +45.3% | +10.3% | -9.6% | +183.3% | -4.8% | +30.2% | +38.2% | -381.4% | -36.1% | -41.8% | |
| ROA | 4.8% | 1.5% | 0.9% | 1.4% | 1.3% | 1.2% | 0.8% | 1.0% | 1.2% | 1.4% | -1.0% | 1.1% | 1.0% |
| — | +25.3% | +15.9% | +50.0% | +8.0% | -13.7% | +178.0% | -9.6% | +23.9% | +30.0% | -361.2% | -39.6% | -42.8% | |
| ROIC | 7.8% | 1.9% | 1.9% | 2.0% | 2.1% | 1.7% | 1.2% | 1.4% | 1.6% | 1.8% | -0.7% | 1.4% | 1.4% |
| — | +10.8% | +62.4% | +47.7% | +27.9% | -2.6% | +267.5% | -4.8% | +17.8% | +15.9% | -261.7% | -19.7% | -33.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Labcorp Holdings Inc.'s Debt/EBITDA ratio is 12.9x — elevated, raising questions about debt serviceability. The current ratio has weakened 6.0% YoY to 1.73x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.83 | 0.83 | 0.83 | 0.83 | 0.77 | 0.78 | 0.90 | 0.94 | 0.74 | 0.75 | 0.75 | 0.80 | 0.71 |
| — | +5.7% | -7.4% | -12.1% | +3.5% | +4.7% | +19.5% | +17.6% | +5.6% | +23.3% | +22.2% | +29.3% | +16.4% | |
| Debt / EBITDA | 3.28 | 12.92 | 12.99 | 12.72 | 11.59 | 13.23 | 18.79 | 18.57 | 13.23 | 12.54 | — | 14.33 | 14.69 |
| — | -2.4% | -30.9% | -31.5% | -12.4% | +5.5% | — | +29.6% | -10.0% | -5.9% | — | +16.1% | +25.6% | |
| Current Ratio | 1.42 | 1.73 | 1.42 | 1.55 | 1.50 | 1.84 | 1.44 | 1.44 | 0.88 | 0.88 | 1.17 | 1.36 | 2.35 |
| — | -6.0% | -1.3% | +7.8% | +71.2% | +109.3% | +23.6% | +5.6% | -62.5% | -46.1% | -22.3% | -21.4% | +23.2% | |
| Quick Ratio | 1.23 | 1.54 | 1.23 | 1.35 | 1.32 | 1.60 | 1.30 | 1.30 | 0.77 | 0.76 | 1.02 | 1.20 | 2.12 |
| — | -3.8% | -4.7% | +4.3% | +71.1% | +111.4% | +26.9% | +7.7% | -63.7% | -48.2% | -24.4% | -22.2% | +22.1% | |
| Interest Coverage | 5.94 | 7.03 | 4.47 | 7.02 | 6.34 | 5.91 | 3.90 | 5.18 | 6.62 | 7.34 | 4.48 | 5.75 | 5.12 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into LH consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LH stock.
Labcorp Holdings Inc.'s current P/E is 24.5x. The average P/E over the last 4 quarters is 24.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Labcorp Holdings Inc.'s current operating margin is 10.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Labcorp Holdings Inc.'s business trajectory between earnings reports.